<DOC>
	<DOCNO>NCT01523236</DOCNO>
	<brief_summary>The objective study evaluate clinical equivalence test formulation mometasone furoate anhydrous 50 mcg/actuation nasal spray ( manufacture Teva Pharmaceutical Industries , Ltd. distribute Teva Pharmaceuticals USA ) market formulation NasonexÂ® ( mometasone furoate monohydrate ) nasal spray , 50 mcg/actuation ( Schering ) patient seasonal allergic rhinitis . In addition , efficacy test reference nasal spray compare placebo nasal spray safety compare .</brief_summary>
	<brief_title>Clinical Equivalence Study Mometasone Nasal Spray , 50 Mcg/Actuation</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Male nonpregnant , nonlactating female 12 year age old . Signed informed consent form , meet criteria current FDA regulation . For patient age majority state study conduct ( 18 year state ) parent legal guardian sign consent form child require sign patient `` assent '' form write way understandable child . If female childbearing potential , negative urine pregnancy test prepare abstain sexual intercourse use reliable method contraception study . In order hormonal birth control consider reliable method patient must regimen least 28 day . Documented positive allergic skin test , perform within previous 12 month , one allergens season time study conduct . A minimum two year previous history seasonal allergic rhinitis pollen/allergen season time study conduct . A score least 6 reflective Total Nasal Symptom Score ( rTNSS ) minimum score least 2 `` nasal congestion '' minimum score least 2 one remain 3 symptom . The patient must meet minimum requirement prior enter placebo leadin period also prior enrol randomize , active treatment period study . Under 12 year age . Females pregnant , lactating , likely become pregnant study . Negative lack document skin allergen test ( perform within previous 12 month ) least one allergens season time study conduct . The result positive skin allergen test result report . Patients suffer chronic sign symptom perennial allergic rhinitis ( PAR ) exclude study unless Investigator assess patient 's current sign symptom clear exacerbation Seasonal Allergic Rhinitis ( SAR ) rather chronic PAR . Patients suffer perennial allergic rhinitis seasonal allergic rhinitis different allergen season time study conduct . Previous history le 2 year seasonal allergic rhinitis pollen/allergen season time study conduct . A total score le 6 reflective Total Nasal Symptom Score ( rTNSS ) score less 2 `` nasal congestion '' score less 2 3 remain symptom . Any patient meet minimum rTNSS requirement start placebo leadin period long meet requirement prior randomize active treatment period study continue active treatment period . History asthma previous two year require chronic therapy . Occasional acute mild exercise induce asthma allowable condition treatment attack restrict betaagonists . Patients nasal condition , include infectious rhinitis , rhinitis medicamentosa , atrophic rhinitis . Clinically significant nasal deformity ( e.g . significantly deform septum , nasal polyp ulcer ) recent nasal surgery trauma completely heal . Sinus infection within previous 30 day history reoccurring sinus infection . Patient start immunotherapy ( include topical desensitization therapy ) change dose immunotherapy within 30 day first placebo leadin dose , likely start immunotherapy change current dose study . Treatment oral Candidiasis within 30 day start study current oral Candidiasis infection . Upper respiratory tract infection within previous 30 day . Patients history tuberculosis . Patients presence glaucoma , cataract , ocular herpes simplex , conjunctivitis , eye infection relate diagnosis SAR within 14 day enrollment . The patient recent exposure ( 30 day ) risk expose chicken pox measles . Patients untreated fungal , bacterial , systemic viral infection within previous 30 day . Use ophthalmic steroid within 14 day nasal , inhale , systemic steroid within 30 day study start . Super high potency topical steroid use study . The use low potency topical corticosteroid allow . The use hormonal contraceptive hormone replacement therapy allow , condition patient stable dose regime least 28 day prior start study remain dose regimen study . Use intranasal systemic secondgeneration antihistamine within 10 day enrollment . Use intranasal cromolyn within 14 day enrollment . Use intranasal systemic firstgeneration antihistamine , leukotriene receptor antagonist nasal decongestant within 3 day enrollment . Use tricyclic antidepressant within 30 day enrollment . Patients attentiondeficit disorder treat methylphenidate containing product stable dose regimen least 30 previous day remain dosing regime throughout study . Desensitization therapy seasonal allergen cause patient 's allergic rhinitis within previous 6 month . Previous SAR and/or PAR proven unresponsive steroid therapy . Any known hypersensitivity mometasone , steroid , component study nasal spray . Significant history current evidence chronic infectious disease , system disorder , organ disorder , medical condition Investigator 's opinion would place study patient undue risk participate could jeopardize integrity study evaluation . Receipt drug part research study within 30 day prior first placebo leadin dose . Planned travel outside local area 2 consecutive day 3 day total , patient 's participation study . Previous participation study . The patient history noncompliance medication regiment treatment protocols previous clinical study . The patient member investigational study staff member family investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>